The effects of atorvastatin on mustard-gas-exposed patients with chronic obstructive pulmonary disease: A randomized controlled trial

Journal of Research in Medical Sciences

Volumn 19, Issue 2, 2014, Pages 99-105

  Ghobadi, Hassan ^a   Lari, Shahrzad M ^b   Pourfarzi, Farhad ^a   Mahmoudpour, Afsoun ^c   Ghanei, Mostafa ^d  

^a ARDABIL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Ardabil University of Medical Science   (Iran)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atorvastatin; COPD; Hs CRP; Sulfur mustard

Indexed keywords

ATORVASTATIN; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; HEMOGLOBIN; MUSTARD GAS; PLACEBO;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; COPD ASSESSMENT TEST; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MALE; PATIENT ASSESSMENT; PULSE OXIMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; WALK DISTANCE TEST;

EID: 84896473506     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Balali-mood M, Hefazi M. The clinical toxicology of sulfur mustard. Arch Iran Med 2005;8:162-79.
2. Veress LA, O'Neill HC, Hendry-Hofer TB, Loader JE, Rancourt RC, White CW. Airway obstruction due to bronchial vascular injury after sulfur mustard analog inhalation. Am J Respir Crit Care Med 2010;182:1352-61.
3. United Nations Security Council, "Report of the specialist appointed by the secretary general to investigate allegation by the Islamic Republic of Iran concerning the use of chemical weapons," Tech. Rep. 3/16433, United Nations Security Council, New York, NY, USA, 1986.
4. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of Lung, Eye, and Skin Lesions as Late Complications in 34,000 Iranians with Wartime Exposure to Mustard Agent. J Occup Environ Med 2003;45:1136-43.
5. Ghanei M, Harandi AA. Long term consequences from exposure to sulfur mustard: A review. Inhal Toxicol 2007;19:451-6.
6. Kehe K, Szinicz L. Medical aspects of sulphur mustard poisoning. Toxicology 2005;214:198-209.
7. Ghanei M, Adibi I. Clinical Review of Mustard Lung. Iran J Med Sci 2007;32:58-65.
8. Ghanei M, Harandi AA. Long term consequences from exposure to sulfur mustard: A review. Inhal Toxicol 2007;19:451-6.
9. Attaran D, Lari SM, Khajehdaluee M, Ayatollahi H, Towhidi M, Asnaashari A, et al. Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases. Hum Exp Toxicol 2009;28:739-45.
10. Mirsadraee M, Ghobadi H, Khakzad MR, Lari SM, Attaran D, Towhidi M, et al. Level of eosinophil cationic protein in sputum of chemical warfare victims. Iran J Basic Med Sci 2011;14:249-55.
11. Attaran D, Lari SM, Towhidi M, Ghobadi-Marallu H, Ayatollahi H, Khajehdaluee M, et al. Interleukin-6 and airfl ow limitation in chemical warfare patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010;5:335-40.
12. Pepys MB, Hirschfi eld GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-12.
13. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun 2001;69:1747-54.
14. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5.
15. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and Interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008;101:530-5.
16. Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-83.
17. Hothersall EJ, Chaudhuri R, McSharry C, Donnelly I, Laff erty J, McMahon AD, et al. Eff ects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax 2008;63:1070-5.
18. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
19. CAT-Iran/Farsi, Version of Sep 10-Mapi Research Institute, GlaxoSmithKline). Available from: http://www.catestonline.org/ english/index_Farsi.htm. [Last accessed on 2013/08].
20. Braganza G, Chaudhuri R, McSharry C, Weir CJ, Donnelly I, Jolly L, et al. Eff ects of short-term treatment with atorvastatin in smokers with asthma--a randomized controlled trial. BMC Pulm Med 2011;7:11-6.
21. Ghanei M, Shohrati M, Jafari M, Ghaderi S, Alaeddini F, Aslani J. N-acetyl cysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test. Basic Clin Pharmacol Toxicol 2008;103:428-32.
22. Yazdani S, Karimfar MH, Imani Fooladi AA, Mirbagheri L, Ebrahimi M, Ghanei M, et al. Nuclear factor_B1/RelA mediates the infl ammation and/or survival of human airway exposed to sulfur mustard. J Recept Signal Transduct Res 2011;31:367-73.
23. Nourani MR, Ebrahimi M, Roudkenar MH, Vahedi E, Ghanei M, Imani Fooladi AA. Sulfur mustard induces expression of metallothionein-1A in human airway epithelial cells. Int J Gen Med 2011;4:413-9.
24. Jafari M, Ghanei M. Evaluation of plasma, erythrocytes, and bronchoalveolar lavage fl uid anti-oxidant defense system in sulfur mustard-injured patients. Clin Toxicol (Phila) 2010;48: 184-92.
25. Shohrati M, Ghanei M, Shamspour N, Babaei F, Abadi MN, Jafari M, et al. Glutathione and malondialdehyde levels in late pulmonary complications of sulfur mustard intoxication. Lung 2010;188:77-83.
26. Ghabili K, Agutter PS, Ghanei M, Ansarin K, Shoja MM. Mustard gas toxicity: The acute and chronic pathological effects. J Appl Toxicol 2010;30:627-43.
27. Ghanei M, Sheyacy M, Abbasi MA, Ani A, Aslani J. Correlation between the degree of air trapping in chest HRCT and cardiopulmonary exercise test parameters: Could HRCT be a predictor of disease severity? Arch Iran Med 2011;14:86-90.
28. Ghobadi H, Sadeghieh-Ahari S, Kameli A, Lari SM. The relationship between COPD Assessment Test (CAT) Scores and Severity of Airfl ow Obstruction in Stable COPD Patients. Tanaff os 2012;11:22-6.
29. Fadaii A, Sohrabpour H, Taherkhanchi B, Bagheri B. Association between COPD Assessment Test (CAT) and Disease Severity Based on Reduction of Respiratory Volumes in Chemical Warfare Victims. Tanaff os 2011;10:38-42.
30. Tsiligianni IG, van der Molen T, Moraitaki D, Lopez I, Kocks JW, Karagiannis K, et al. Assessing health status in COPD. A headto- head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm Med 2012;20:12-20.